CompanyGraph
Jacobio Pharmaceuticals Group Co., Ltd.
1167 · HKEX · China
Price data from its 77V listing on XSTU, quoted in EUR
jacobiopharma.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $7.94M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 2.85: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.27BHKD799.80M · vs all stocks (USD)
Revenue (TTM)
62.29MCNY7.94M · vs all stocks (USD)
Profit Margin
-272.73%vs Biotechnology peers
Beta
0.2950xvs all stocks
52-Week Change
-32.83%vs all stocks
Market Capitalization
6.27BHKD799.80M · vs all stocks (USD)
Enterprise Value
3.71BHKD472.88M · vs all stocks (USD)
Forward P/E
-80.62xvs Biotechnology peers
Price to Sales (TTM)
75.40xvs Biotechnology peers
Price to Book (MRQ)
4.53xvs Biotechnology peers
Enterprise to Revenue
59.55xvs Biotechnology peers
Enterprise to EBITDA
-20.74xvs Biotechnology peers
Profit Margin
-272.73%vs Biotechnology peers
Operating Margin
-1292.19%vs Biotechnology peers
Return on Assets (TTM)
-7.80%vs Biotechnology peers
Return on Equity (TTM)
-17.24%vs Biotechnology peers
Revenue (TTM)
62.29MCNY7.94M · vs all stocks (USD)
Revenue per Share (TTM)
0.0690CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-95.00%vs Biotechnology peers
Gross Profit (TTM)
61.60MCNY7.85M · vs all stocks (USD)
EBITDA (TTM)
-178.85MCNY-22.80M · vs all stocks (USD)
Net Income (TTM)
-169.89MCNY-21.66M · vs all stocks (USD)
Operating Cash Flow (TTM)
-245.61MCNY-31.31M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-67.99MCNY-8.67M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
53.52MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
593.00KCNYFY2025 · Dec 31, 2025Gross Profit
52.93MCNYFY2025 · Dec 31, 2025Operating Income
-166.24MCNY-24.65M · vs all stocks (USD)
Pre-tax Income
-145.98MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-145.98MCNYFY2025 · Dec 31, 2025EBIT
-133.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-128.51MCNYFY2025 · Dec 31, 2025Research & Development
188.59MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
8.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
31.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.94MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1900CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
774.51MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
774.51MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-145.98MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-167.38MCNYFY2025 · Dec 31, 2025Free Cash Flow
-168.48MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
373.78MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-145.98MCNYFY2025 · Dec 31, 2025Stock-based Compensation
4.48MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-18.76MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.70MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-414.00KCNYFY2025 · Dec 31, 2025Capital Expenditures
-1.10MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-567.00KCNYFY2025 · Dec 31, 2025Net Acquisitions
114.54MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.62BCNYFY2025 · Dec 31, 2025Sale of Investments
2.37BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-141.75MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
114.87MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-92.17MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-11.28MCNYFY2025 · Dec 31, 2025Other Financing Charges
45.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
56.43MCNYFY2025 · Dec 31, 2025Shares Outstanding
787.06MSharesUpdated Aug 19, 2026Float Shares
411.54MSharesUpdated Aug 19, 2026% Held by Insiders
35.75%vs all stocks
% Held by Institutions
10.47%vs all stocks
Total Cash (MRQ)
1.32BCNY168.20M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.44CNYUpdated Aug 19, 2026Total Debt (MRQ)
192.22MCNY24.51M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2143xvs Biotechnology peers
Current Ratio (MRQ)
5.10xvs Biotechnology peers
Book Value per Share (MRQ)
1.14CNYUpdated Aug 19, 2026Total Assets
1.30BCNY193.43M · vs all stocks (USD)
Total Current Assets
1.15BCNYFY2025 · Dec 31, 2025Total Liabilities
533.70MCNYFY2025 · Dec 31, 2025Total Non-current Assets
150.54MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
307.40MCNYFY2025 · Dec 31, 2025Total Current Liabilities
226.29MCNYFY2025 · Dec 31, 2025Cash
373.78MCNYFY2025 · Dec 31, 2025Cash Equivalents
569.88MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
943.65MCNYFY2025 · Dec 31, 2025Other Short-term Investments
160.03MCNYFY2025 · Dec 31, 2025Accounts Receivable
8.89MCNYFY2025 · Dec 31, 2025Accounts Payable
43.52MCNYFY2025 · Dec 31, 2025Short-term Debt
15.43MCNYFY2025 · Dec 31, 2025Long-term Debt
149.74MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
157.30MCNYFY2025 · Dec 31, 2025Common Stock (Book)
523.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-3.50BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
770.63MCNY114.28M · vs all stocks (USD)
Treasury Stock
15.84MCNYFY2025 · Dec 31, 202552-Week Low
3.98HKDUpdated Aug 19, 202652-Week High
11.80HKDUpdated Aug 19, 202652-Week Change
-32.83%vs all stocks
Beta
0.2950xvs all stocks
50-Day MA
4.79HKDUpdated Aug 19, 2026200-Day MA
6.29HKDUpdated Aug 19, 2026Avg 10-Day Volume
3.88MSharesUpdated Aug 19, 2026Avg 30-Day Volume
3.13MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.2200CNYUpdated Aug 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.85: safe zoneNotable
Altman Z-Score: 2.85
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $7.94M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,941,520.897Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
D&D Pharmatech Inc.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedDecline With Range Expansion And DrawdownHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Krishana Phoschem Ltd.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedDecline With Range Expansion And Drawdown
Wave Life Sciences Ltd.
2 interpretationsDecline With Range Expansion And DrawdownHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC